Study guide
20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
UEMS European Board of Dermatovenereology Diploma Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Eligibility & Examination Regulations
1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition
2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology
2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns
3 Chapter 3: Dermatopathology & Diagnostic Procedures
3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy
4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology
4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance
5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease
5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
6 Chapter 6: Hair, Nails & Pigmentary Disorders
6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation
7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses
8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease
8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease
9 Chapter 9: Autoimmune Bullous Diseases
9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
10 Chapter 10: Eczematous Disorders, Urticaria & Allergology
10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis
11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
12 Chapter 12: Paediatric & Genetic Dermatology
12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa
13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections
13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections
14 Chapter 14: Viral & Fungal Cutaneous Infections
14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses
15 Chapter 15: Sexually Transmitted Infections & Genital Infections
15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours
17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases
18 Chapter 18: Melanocytic Naevi & Melanoma
18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma
19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas
19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas
20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing
20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures
21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy
22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision
22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review
20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
Key Takeaways Explain This Topic AI
Hydroxychloroquine should not exceed 5 mg/kg of actual body weight per day, with baseline eye examination and annual retinal screening after 5 years of use, or sooner with risk factors.
Dapsone causes dose-related haemolysis and methaemoglobinaemia in all patients, so G6PD activity must be checked before starting and blood counts monitored closely in the first months.
Colchicine combined with strong CYP3A4 or P-glycoprotein inhibitors such as clarithromycin can cause fatal colchicine toxicity.
EGFR inhibitors cause a papulopustular acneiform eruption in most patients, and pre-emptive oral doxycycline with emollients, sunscreen, and mild topical steroids reduces its severity.
Vemurafenib and other BRAF inhibitors used alone can cause keratoacanthomas and squamous cell carcinomas through paradoxical MAPK activation, which is reduced by combining them with a MEK inhibitor.
Last updated: September 2026
20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
Topical corticosteroids, calcineurin inhibitors, retinoids, vehicles, immunosuppressants, biologics, and phototherapy are covered in the other therapeutics sections. This section adds the remaining drug groups and the rules for special populations.
Principles of Topical Prescribing
Choose the vehicle for the site and the state of the skin (see the vehicle table in the topical therapy section), and prescribe an adequate quantity using fingertip units.
Preservatives and fragrances in topical products are common contact allergens (for example methylisothiazolinone and some parabens in leave-on products).
Wet wraps and occlusion increase penetration and effect, and also systemic absorption.
Children absorb more topical drug relative to body weight, because their surface-area-to-weight ratio is higher.
Topical Anti-Infectives
Group Examples Points
Antibiotics Fusidic acid, mupirocin, retapamulin, ozenoxacin Use short courses because resistance develops quickly (fusidic acid-resistant S. aureus is common). Mupirocin is kept mainly for MRSA decolonisation
Antiseptics Chlorhexidine, povidone-iodine, octenidine, hypochlorite Preferred for many superficial infections to reduce antibiotic use. Chlorhexidine can cause contact allergy and anaphylaxis
Antifungals Azoles (clotrimazole, ketoconazole), terbinafine, ciclopirox, amorolfine, nystatin Nystatin treats Candida only, not dermatophytes
- Antiparasitics Permethrin, ivermectin cream, benzyl benzoate, dimeticone See the parasitic infections section
- Systemic Anti-Infectives Used in Dermatology
Drug Key Adverse Effects and Interactions
Doxycycline, lymecycline Photosensitivity and photo-onycholysis, oesophagitis (take upright with water); avoid in pregnancy and young children (tooth staining); never combine with isotretinoin (intracranial hypertension)
Minocycline Blue-black pigmentation, dizziness, DRESS, drug-induced lupus, and autoimmune hepatitis; generally no longer preferred
Macrolides QT prolongation; clarithromycin and erythromycin inhibit CYP3A4 (interactions with statins, ciclosporin, colchicine)
Co-trimoxazole SJS/TEN, marrow suppression, hyperkalaemia; dangerous with methotrexate (additive folate antagonism)
- Clindamycin Clostridioides difficile colitis
- Flucloxacillin Cholestatic hepatitis, more common in older people and longer courses
Rifampicin Strong enzyme inducer (reduces hormonal contraception, anticoagulants, and many other drugs); orange urine and tears
Terbinafine Liver injury, taste loss; can trigger subacute cutaneous lupus and psoriasis flares
Itraconazole Strong CYP3A4 inhibitor ; avoid in heart failure ; capsules need food and stomach acid for absorption
Fluconazole QT prolongation; CYP2C9 and CYP3A4 inhibition
Griseofulvin Enzyme inducer, photosensitivity; teratogenic; men should avoid fathering a child for several months after treatment
Voriconazole Phototoxicity ; long-term use is linked to squamous cell carcinoma and melanoma and to periostitis
Antihistamines
First-generation (for example chlorphenamine, hydroxyzine): sedating and anticholinergic. Avoid them in older people (falls, confusion) and do not rely on them for night-time itch in the long term.
Second-generation (cetirizine, levocetirizine, loratadine, desloratadine, fexofenadine, bilastine, rupatadine): first-line for urticaria and can be increased up to four times the licensed dose under the urticaria guideline (see the urticaria section).
In pregnancy , loratadine and cetirizine have the most safety data.
Antimalarials
Drug Key Points
Hydroxychloroquine Up to 5 mg/kg actual body weight per day . Retinopathy screening: baseline examination, then annually after 5 years (earlier with kidney disease, tamoxifen, or higher doses). Also QT prolongation, hypoglycaemia, blue-grey pigmentation, and occasional psoriasis flares
Chloroquine Higher retinopathy risk; dose up to about 2.3 mg/kg actual body weight per day
Quinacrine (mepacrine) No retinal toxicity; causes yellow skin; can be added to hydroxychloroquine in refractory cutaneous lupus. Availability varies
Antimalarials are used for cutaneous lupus, dermatomyositis skin disease, lichen planopilaris, sarcoidosis, polymorphic light eruption, and porphyria cutanea tarda (low dose).
Dapsone
Mechanism: anti-neutrophil effects, including inhibition of myeloperoxidase , plus antibacterial action against M. leprae .
Uses: dermatitis herpetiformis, linear IgA disease, bullous lupus, erythema elevatum diutinum, urticarial vasculitis, other neutrophilic dermatoses, and leprosy.
Adverse effects:
Haemolysis (in everyone, dose-related; severe in G6PD deficiency , so test G6PD before starting).
Methaemoglobinaemia (grey-blue cyanosis, breathlessness; measured with co-oximetry).
Agranulocytosis , usually in the first 3 months.
Dapsone hypersensitivity syndrome (a DRESS-like reaction; linked to HLA-B*13:01 in Asian populations), hepatitis, and peripheral motor neuropathy.
Monitoring: blood count frequently (for example weekly) in the first month, then less often; liver tests and methaemoglobin levels as indicated.
Colchicine and Thalidomide
Colchicine inhibits microtubule assembly in neutrophils. It is used for Behçet disease , neutrophilic dermatoses, leucocytoclastic vasculitis, and recurrent aphthae. Diarrhoea is common. Strong CYP3A4 or P-glycoprotein inhibitors (clarithromycin, ciclosporin, some azoles) can cause fatal toxicity , and the dose must be reduced in kidney impairment.
Thalidomide is used for erythema nodosum leprosum , refractory cutaneous lupus, Behçet disease, and prurigo. It is a severe teratogen (phocomelia) and needs a strict pregnancy prevention programme. It also causes dose-related peripheral neuropathy , sedation, and venous thromboembolism.
Special Populations
Population Key Rules
Pregnancy Generally acceptable: emollients, topical steroids (use very potent steroids sparingly), azelaic acid, penicillins, cephalosporins, macrolides, prednisolone, narrowband UVB, ciclosporin when essential, certolizumab pegol. Avoid: oral and topical retinoids, methotrexate, mycophenolate, tetracyclines (from the second trimester), JAK inhibitors, thalidomide, antiandrogens, griseofulvin, podophyllotoxin
Breastfeeding Most topical agents are compatible (avoid applying to the nipple area); check each systemic drug in a lactation database
Children Weight-based dosing; higher topical absorption (risk of adrenal suppression and toxicity from salicylic acid or lidocaine-prilocaine cream, including methaemoglobinaemia in infants); avoid tetracyclines in young children
Older adults Reduced kidney function, polypharmacy and interactions, falls with sedating drugs, fragile skin, and practical limits on applying topical treatments
Kidney or liver impairment Methotrexate is contraindicated in significant kidney impairment; adjust antivirals, gabapentinoids, and colchicine; avoid terbinafine in liver disease
Cutaneous Toxicity of Cancer Therapy
Drug Class Typical Skin Effects Management
EGFR inhibitors (cetuximab, panitumumab, erlotinib, gefitinib, afatinib, osimertinib) Papulopustular (acneiform) eruption in most patients, without comedones , on the face and upper trunk; xerosis and fissures; paronychia and periungual pyogenic granulomas ; trichomegaly and curly hair Pre-emptive oral doxycycline (or minocycline) for about 6 weeks with emollients, sunscreen, and a mild topical steroid; dose changes by severity grade. The rash severity often correlates with tumour response
BRAF inhibitors (vemurafenib, dabrafenib, encorafenib) Keratoacanthomas and squamous cell carcinomas (paradoxical MAPK activation), UVA photosensitivity (vemurafenib), keratosis pilaris-like and verrucal keratoses, hand-foot skin reaction, panniculitis Combining with a MEK inhibitor greatly reduces the proliferative lesions; excise SCCs; sun protection
Multikinase inhibitors (sorafenib, sunitinib, regorafenib) Hand-foot skin reaction : painful hyperkeratotic plaques on pressure areas of palms and soles Urea creams, padding, and dose changes
Chemotherapy (capecitabine, 5-fluorouracil, liposomal doxorubicin) Hand-foot syndrome (palmar-plantar erythrodysaesthesia): tender red swelling and peeling Cooling, emollients, dose changes
Other chemotherapy effects Anagen alopecia; taxane nail changes; bleomycin flagellate pigmentation; cytarabine neutrophilic eccrine hidradenitis; toxic erythema of chemotherapy; radiation recall; anthracycline extravasation (dexrazoxane) Treat by cause
Immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) Itch and maculopapular rash (the most common), lichenoid and psoriasiform eruptions, vitiligo-like depigmentation (in melanoma, linked to better outcomes), bullous pemphigoid , and rarely SJS/TEN Grade by severity. Topical steroids for mild reactions; systemic steroids and pausing treatment for severe reactions; many patients can continue immunotherapy